CN115261355A - AMPK alpha 1 succinylation modification and application - Google Patents
AMPK alpha 1 succinylation modification and application Download PDFInfo
- Publication number
- CN115261355A CN115261355A CN202211116713.5A CN202211116713A CN115261355A CN 115261355 A CN115261355 A CN 115261355A CN 202211116713 A CN202211116713 A CN 202211116713A CN 115261355 A CN115261355 A CN 115261355A
- Authority
- CN
- China
- Prior art keywords
- ampk
- succinylation
- lung cancer
- modification
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11031—[Hydroxymethylglutaryl-CoA reductase (NADPH)] kinase (2.7.11.31)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention discloses AIF1 succinylation modification and application, AMPK alpha 1 is subjected to succinylation modification at a 266 th lysine residue, the succinylation modification of the 266 th lysine residue of the AMPK alpha 1 is obviously higher than that of tissues beside cancer, the biological function of the AMPKA1 is influenced, the lung cancer cell survival and growth promoting and maintaining effects are realized, and the change of the succinylation level can be used as a marker and a target spot for the occurrence and development of lung cancer.
Description
Technical Field
The invention relates to the technical field of biomedicine. In particular to AMPK alpha 1 succinylation modification and application.
Background
Adenosine activated protein kinase alpha 1 (AMPK) can be allosterically activated by adenosine monophosphate, and is a trimer consisting of alpha, beta and gamma subunits, wherein the alpha subunit comprises alpha 1 and alpha 2 subtype subtypes, the beta subunit comprises beta 1 and beta 2, and the gamma subunit comprises gamma 1, gamma 2 and gamma 3, wherein the alpha subunit plays a catalytic role and determines the activity of a protein kinase complex, the beta and gamma subunits play an important role in maintaining the stability and the substrate specificity of the trimer, and AMP/ADP, AMPK upstream kinase (liver kinase B1 (LKB 1), transforming growth factor beta activated protein kinase 1 (TAK 1) and calcium/calmodulin dependent protein kinase-beta (CaMKK-beta)) in an organism can directly or indirectly activate the AMPK; in addition, AMPK can be activated by studying surface DNA damage, and can influence the growth of NSCLC cells through the regulation of autophagy and apoptosis, the regulation of carbohydrate metabolism, the regulation of lipid metabolism, the regulation of protein metabolism and the regulation of mitochondrial function under different environments.
Although research on lung cancer is advanced through continuous exploration of researchers, the occurrence and development mechanisms of lung cancer are still not completely clear, and with continuous and intensive research on cancer, the researchers find that the post-translational covalent modification change of cancer cell proteins has a very close relationship with the occurrence and development of cancer, which suggests that the post-translational covalent modification transformation mechanism of cancer cell proteins may become one of important breakthrough for preventing and treating cancer.
The succinylation modification can regulate gene expression and various metabolic processes, the abnormality of the succinylation modification is closely related to the occurrence and development of various diseases including tumors, heart metabolic diseases, liver metabolic diseases, nervous system diseases and the like, the succinylation modification is known to be related to various malignant tumors including intestinal cancer, lung cancer, skin melanoma, hepatocellular carcinoma, osteosarcoma, nervous system malignant tumors, renal cell carcinoma, thyroid cancer, colon cancer and the like, and whether the succinylation site exists in AMPK alpha 1 or not and the influence of the succinylation site on the biological function of AMPK alpha 1 and the relation with the occurrence and development of lung cancer are not clear in the prior art at present.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide AMPK alpha 1 succinylation modification and application, wherein AMPK alpha 1 is succinylated at a 266 th lysine residue (K266), so that the AMPK alpha 1 has the effect of promoting and maintaining the survival and growth of lung cancer cells, and the change of the succinylation level can be used as a marker and a target point for the occurrence and development of lung cancer.
In order to solve the technical problems, the invention provides the following technical scheme:
AMPK α 1 is succinylated and AMPK α 1 is succinylated at lysine residue 266.
The application of AMPK alpha 1 in the succinylation modification of lysine residue at the 266 th site as a marker and a target for the occurrence and development of lung cancer.
The application of AMPK alpha 1 in the preparation of a preparation for promoting the growth, proliferation and/or migration of tumor cells or cancer cells by succinylation modification of lysine residue at a 266 th site.
Furthermore, the tumor cell or the cancer cell is a lung cancer cell.
The AMPK alpha 1 is applied to the preparation of antitumor drugs through succinylation modification of lysine residue at a 266 th site.
The application of AMPK alpha 1 in the preparation of cancer diagnosis reagents or kits through succinylation modification of lysine residue at the 266 th site.
Further, the cancer is lung cancer.
Use of succinylation modification of AMPK α 1 at lysine residue at position 266 in the preparation of a lung cancer cell sample.
Use of succinylation modification of AMPK α 1 at lysine residue at position 266 in the preparation of a reagent or kit for verifying succinylation of AMPK α 1.
A product, the active ingredient of which comprises AMPK alpha 1 with succinylation modification at the 266 th lysine residue, and the product has at least one of the following functions (1) to (5):
(1) Predicting the risk of the occurrence and development progress of the lung cancer; (2) an increase is indicative of lung cancer with a poor prognosis; (3) promoting and maintaining the survival and growth of the lung cancer cells; (4) the target point for treating lung cancer; and (5) the polypeptide is used as a drug target for treating lung cancer. .
The technical scheme of the invention achieves the following beneficial technical effects:
the AMPK alpha 1 is succinylated at the 266 th site lysine residue (K266) to remarkably increase the growth of lung cancer A549 cells, can predict the risk of the occurrence and development progress of the lung cancer, can be used as a target for treating the lung cancer, is further applied to the prevention and treatment and prognosis of other tumor cells, provides a new diagnosis method for clinically diagnosing the lung cancer on a molecular level, and provides a new drug target for the treatment of the lung cancer
Drawings
FIG. 1 is a schematic diagram showing the succinylation modification of AMPK alpha 1 and the expression level of AMPK alpha 1 modified by K266 succinylation;
FIG. 2 is a schematic diagram showing the correlation between the level of AMPK α 1 succinylation and prognosis for the modification and use of AMPK α 1 succinylation according to the present invention;
in fig. 2, number at risk represents the Number of persons for which an end event has not occurred in the Time node corresponding to Time;
FIG. 3 is a schematic diagram showing the influence of the succinylation modification of AMPK alpha 1 and the K266 succinylation modification of AMPK alpha 1 on the growth of lung cancer;
in FIG. 3: A. tumor mass volume; B. tumor mass weight, { fraction: p is less than 0.01;
wild-type AIF1: lung cancer cells expressing AMPK α 1;
k266 succinylation modified AMPK α 1: lung cancer cells expressing lysine succinylation-modified AMPK α 1 at position 266.
Detailed Description
Example 1
In view of that the succinylation modification of AMPK alpha 1 is not disclosed yet, the embodiment provides a new AMPK alpha 1 succinylation modification mode, namely that AMPK alpha 1 is succinylated at a 266 th lysine residue K66, lysine at 266 th position of wild AMPK alpha 1 is mutated into glutamic acid, succinylated AMPK alpha 1 is simulated, immunohistochemistry is used for analyzing the succinylation level of lung cancer tissue of a clinical specimen at K66, and the result shows that the simulated succinylated AMPK alpha 1 remarkably increases the growth of lung cancer A549 cells inoculated in a nude mouse, so that the 266 th lysine succinylated AMPK alpha 1 has the effect of promoting and maintaining the survival and growth of lung cancer cells, the change of the succinylation level at the site can be used as a marker for monitoring the occurrence and development of the lung cancer, the prognosis of the occurrence and development of the lung cancer can be predicted, the lung cancer is predicted to be poor, a new diagnosis method is provided for clinically diagnosing the lung cancer at a molecular level, and a new drug target is provided for the treatment of the lung cancer.
AMPK alpha 1 subunit is a catalytic subunit of AMPK, and is widely distributed in different tissues and organs, the activated AMPK alpha 1 can also inhibit the expression of metabolism-related enzymes (glucose transporter 1, hexokinase 1 and lactate dehydrogenase) related to Warburg effect, which can cause the reduction of glucose uptake and lactate level of tumor cells, so as to inhibit the growth of NSCLC cells, after the AMPK alpha 1 undergoes succinylation modification at a 266 th site lysine residue K66, the charge is changed, and the recognition and cleavage of protease on AIF1 are inhibited, so that AIF1 cannot perform apoptosis function, AIF1 in cells resists enzyme digestion, and the enzymatic activity of AMPK alpha 1 is inhibited, so that the regulation of autophagy and apoptosis, the regulation of carbohydrate metabolism, the regulation of lipid metabolism, the regulation of protein metabolism and the regulation of mitochondrial function are inhibited to promote the growth of lung cancer cells, maintain the oxidative respiration required by cell survival, and improve the glucose uptake and lactate level of the lung cancer cells, therefore, the AMPK alpha 1 succinylation expression level can be used as a relevant target for treating lung cancer.
Example 2
The materials, reagents and the like used in the following examples are commercially available unless otherwise specified, and the quantitative tests in the following examples were carried out in triplicate to obtain an average.
This example analyzes the level of succinylation modification of the lysine residue at position 266 (K266) in AMPK α 1, a clinical specimen lung cancer tissue, by immunohistochemistry.
Detecting the succinylation level of the 266 th lysine residue of AMPK alpha 1 in cancer tissues and paracarcinoma tissues by using an antibody which specifically recognizes the succinylation of AMPK alpha 1 at the position of K266, wherein the tissue sample is human lung cancer tissues, and the total number of the lung cancer tissues is 85 and the paracarcinoma tissues is 85.
In the analysis results, the interpretation method of the original experimental data is as follows:
judging the intensity of cytoplasmic staining and the positive rate of staining of AMPK alpha 1 succinylation analysis; cancer tissue and paracarcinoma tissue (epithelium) were interpreted separately.
Standardization protocol for raw experimental data:
antibody: AMPK α 1 succinylated antibody (K266);
staining intensity scoring: score 0 (negative), score 1 (1 +), score 2 (2 +), score 3 (3 +);
scoring of staining positive rate: 0% -100%;
total score: the product of "staining intensity score" and "staining positive rate" (0-300%);
the analytical results were as follows:
1. differential analysis of antibody expression in cancer and paracancerous tissues
1-1, lung cancer tissues and paracarcinoma tissues were analyzed for AMPK α 1 succinylation levels (K266) as shown in the following table:
* Significance statistics (p < 0.05)
FIG. 1 is a graph showing the expression level of K266 succinylated modified AMPK alpha 1, and in combination with FIG. 1, it was found that succinylated AMPKa1 protein was significantly higher in the lung cancer tissues than in the paracarcinoma tissues (p < 0.001) according to Mann-Whitney test.
Correlation analysis of 1-2, AMPK alpha 1 succinylation levels and patient prognosis
With reference to FIG. 2, according to the results of Kaplan-Meier survival analysis, it is known that the high expression of succinylated AMPKa1 protein is significantly related to poor prognosis of lung cancer (p < 0.01).
1-3, K266 succinylation modified AMPK alpha 1 for promoting lung cancer growth
Referring to FIG. 3, the lung cancer cells expressing AMPK α 1 and the lung cancer A549 cells expressing the 266 th lysine succinylation-modified AMPK A1 were inoculated into nude mice, and fed into the animals for 21 days, and tumor tissues were analyzed and compared, and as a result, the average mass of the tumor mass of the wild-type AMPK A1 was 0.05g, the average mass of the tumor mass of the K266 succinylation-modified AMPKA1 was 0.18g, and the growth rate of the lung cancer cells expressing the K266 succinylation-modified AMPKA1 was significantly higher than that of the lung cancer cells expressing AMPKA1, and P was less than 0.01.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications are possible which remain within the scope of the appended claims.
Claims (10)
- AMPK α 1 succinylation modification, wherein AMPK α 1 is succinylated at lysine residue 266.
- 2. Use of AMPK α 1 succinylation modification as defined in claim 1 as a marker and target for the development of lung cancer.
- 3. Use of AMPK α 1 succinylation modification as defined in claim 1 for the preparation of a formulation for promoting growth, proliferation and/or migration of tumor or cancer cells.
- 4. The AMPK α 1 succinylated modification of claim 3, wherein said tumor or cancer cell is a lung cancer cell.
- 5. Use of AMPK α 1 succinylation modification according to claim 1 for the preparation of an antitumor medicament.
- 6. Use of AMPK α 1 succinylation modification according to claim 1 for the preparation of a cancer diagnostic reagent or kit.
- 7. The AMPK alpha 1 succinylation modification of claim 6, wherein said cancer is lung cancer.
- 8. Use of AMPK α 1 succinylation modification according to claim 1 for the preparation of a lung cancer cell sample.
- 9. Use of AMPK α 1 succinylation modification according to claim 1 for the preparation of a reagent or kit for verifying succinylation of AMPK α 1.
- 10. A product, wherein the active ingredient of said product comprises AMPK alpha 1 modified by succinylation at lysine 266, said product having at least one of the following functions (1) - (5):(1) Pre-judging the risk of the occurrence, development and progression of lung cancer; (2) an increase is indicative of lung cancer, poor prognosis; (3) promoting and maintaining lung cancer cell survival and growth; (4) the target spot for treating lung cancer; and (5) the polypeptide is used as a drug target for treating lung cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211116713.5A CN115261355B (en) | 2022-09-14 | 2022-09-14 | AMPK alpha 1 succinylation modification and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211116713.5A CN115261355B (en) | 2022-09-14 | 2022-09-14 | AMPK alpha 1 succinylation modification and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115261355A true CN115261355A (en) | 2022-11-01 |
| CN115261355B CN115261355B (en) | 2023-07-28 |
Family
ID=83756334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211116713.5A Active CN115261355B (en) | 2022-09-14 | 2022-09-14 | AMPK alpha 1 succinylation modification and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115261355B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116879563A (en) * | 2023-07-20 | 2023-10-13 | 南昌大学 | Application of 317 th lysine succinylated modified lactate dehydrogenase C as weak sperm disease development marker or target |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050898A2 (en) * | 2002-12-04 | 2004-06-17 | Elixir Pharmaceuticals, Inc. | Ampk pathway components |
| CN103827083A (en) * | 2011-08-08 | 2014-05-28 | 韩诺生物制药株式会社 | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| US20190316208A1 (en) * | 2018-04-13 | 2019-10-17 | Duke University | Predictive biomarkers for cancer immunotherapy and methods of using same |
| CN110403940A (en) * | 2019-07-12 | 2019-11-05 | 山东省立医院 | Application of the succinylation related preparations in regulation mitochondria OCR |
-
2022
- 2022-09-14 CN CN202211116713.5A patent/CN115261355B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050898A2 (en) * | 2002-12-04 | 2004-06-17 | Elixir Pharmaceuticals, Inc. | Ampk pathway components |
| CN103827083A (en) * | 2011-08-08 | 2014-05-28 | 韩诺生物制药株式会社 | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| US20190316208A1 (en) * | 2018-04-13 | 2019-10-17 | Duke University | Predictive biomarkers for cancer immunotherapy and methods of using same |
| CN110403940A (en) * | 2019-07-12 | 2019-11-05 | 山东省立医院 | Application of the succinylation related preparations in regulation mitochondria OCR |
Non-Patent Citations (4)
| Title |
|---|
| WU SHENGNAN等: "AMPK, Mitochondrial Function, and Cardiovascular Disease", INT. J. MOL. SCI, vol. 21, pages 1 - 33 * |
| XIA Y等: "5\'-AMP-activated protein kinase catalytic subunit alpha-1 isoform 1 [Homo sapiens]", GENEBANK, pages 1 - 5 * |
| 杨鑫: "含有多种酶活性的SIRT5蛋白在细胞代谢中的功能", 中国科学: 生命科学, vol. 45, no. 11, pages 1069 - 1073 * |
| 黄小琴等: "腺苷酸活化蛋白激酶α1在肿瘤中的研究进展", 华西医学, vol. 37, no. 3, pages 460 - 467 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116879563A (en) * | 2023-07-20 | 2023-10-13 | 南昌大学 | Application of 317 th lysine succinylated modified lactate dehydrogenase C as weak sperm disease development marker or target |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115261355B (en) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Therapeutic drug monitoring of 5-fluorouracil | |
| Yen et al. | Should DPD analysis be required prior to prescribing fluoropyrimidines? | |
| Roszkowski et al. | Oxidative damage DNA: 8-oxoGua and 8-oxodG as molecular markers of cancer | |
| Russell | Clinical relevance of polyamines as biochemical markers of tumor kinetics. | |
| Lambrou et al. | Arsenic exposure and DNA methylation among elderly men | |
| Pan et al. | Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients | |
| Freedman et al. | Relationships between electrochemical skin conductance and kidney disease in type 2 diabetes | |
| Santana Bezerra et al. | The MTHFR promoter hypermethylation pattern associated with the A1298C polymorphism influences lipid parameters and glycemic control in diabetic patients | |
| CN115261355A (en) | AMPK alpha 1 succinylation modification and application | |
| Cao et al. | An evaluation of the accuracy of a flash glucose monitoring system in children with diabetes in comparison with venous blood glucose | |
| Alfaqih et al. | Single nucleotide polymorphism in the ADIPOQ gene modifies adiponectin levels and glycemic control in type two diabetes mellitus patients | |
| Li et al. | Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave’s disease: a metabolomic approach | |
| Tavares et al. | Effect of the peroxisome proliferator-activated receptor-γ C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus | |
| Wünsch Filho et al. | Modern cancer epidemiological research: genetic polymorphisms and environment | |
| TWI334929B (en) | Screening method for prediabetic state and regent for screening | |
| Pesta et al. | NDUFB6 polymorphism is associated with physical activity-mediated metabolic changes in type 2 diabetes | |
| Trewyn et al. | Urinary nucleosides in leukemia: laboratory and clinical applications | |
| Kirkpatrick et al. | Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis | |
| Maguolo et al. | Cardiovascular risk factors in children and adolescents with type 1 diabetes mellitus: The role of insulin resistance and associated genetic variants | |
| Sögüt et al. | The activities of serum adenosine deaminase and xanthine oxidase enzymes in Behcet's disease | |
| Gloria-Bottini et al. | Cytosolic low molecular weight protein-tyrosine phosphatase activity and clinical manifestations of diabetes | |
| CN111500709A (en) | Metabolic disease gene detection and clinical depth data analysis method | |
| Shine et al. | Electrophoretic assessment of aqueous and serum neurone-specific enolase in retinoblastoma and ocular malignant melanoma. | |
| Khosroshahi et al. | The impact of malnutrition on mortality and complications of hematopoietic stem cell transplantation in patients with acute leukemia | |
| WO2022186652A1 (en) | Method and kit for diagnosing diabetes by using tears |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |